---
document_datetime: 2025-11-23 07:07:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/hepacare.html
document_name: hepacare.html
version: success
processing_time: 0.0433714
conversion_datetime: 2025-12-24 20:59:06.054466
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Hepacare

[RSS](/en/individual-human-medicine.xml/66249)

##### Withdrawn

This medicine's authorisation has been withdrawn

hepatitis B surface antigens recombinant (S, pre-S1, pre-S2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (C127I) cells]

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 4 August 2000 the European Commission granted a marketing authorisation for the whole European Union to Medeva Pharma Limited, now known as Celltech Pharmaceuticals Ltd., for Hepacare (triple antigen hepatitis B recombinant vaccine), indicated for active immunisation against hepatitis B virus infection in non-immune adults (â‰¥18 years).

Hepacare was not marketed anywhere in the world. On 23 August 2002 the Marketing Authorisation Holder notified the European Commission of its decision to voluntarily withdraw the marketing authorisation for Hepacare for commercial reasons. Alternatives are available in Europe, either as mono-component or combined vaccines.

On 23 October 2002 the European Commission adopted the decision withdrawing the marketing authorisation for the medicinal product for human use Hepacare. Pursuant to this decision the European Public Assessment Report for Hepacare has been removed from this website.

## Product information

23/10/2002

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Hepacare Active substance hepatitis B surface antigens recombinant (S, pre-S1, pre-S2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (C127I) cells] International non-proprietary name (INN) or common name hepatitis B surface antigens recombinant (S, pre-S1, pre-S2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (C127I) cells] Therapeutic area (MeSH)

- Hepatitis B
- Immunization

Anatomical therapeutic chemical (ATC) code J07BC

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

This vaccine is indicated for active immunisation against hepatitis B virus infection in non-immune adults (&gt;=18 years). The specific at risk categories to be immunised are to be determined on the basis of official recommendations.

## Authorisation details

EMA product number EMEA/H/C/000261 Marketing authorisation holder

Evans Vaccines Ltd.

Evans Vaccines Limited

Marketing authorisation issued 04/08/2000 Withdrawal of marketing authorisation 23/10/2002

**This page was last updated on** 17/12/2002

## Share this page

[Back to top](#main-content)